Freedom Forever Acquires a 50% Stake in Boundless Energy

MARLBOROUGH, MA / ACCESSWIRE / January 19, 2024 / Boundless Energy Inc. and Freedom Forever, two key players in the renewable energy sector, are pleased to announce a deepening of their partnership. The decision to reinforce and further integrate both …

MARLBOROUGH, MA / ACCESSWIRE / January 19, 2024 / Boundless Energy Inc. and Freedom Forever, two key players in the renewable energy sector, are pleased to announce a deepening of their partnership. The decision to reinforce and further integrate both organizations aims to enhance company stability and longevity while creating unique ownership opportunities for sales representatives and leaders alike.

Riley Traveller, the CEO of Boundless Energy, stated, "This partnership makes it possible for every person in our organization to own a piece of Freedom Forever. We’ve chosen to make equity available to everyone, not just the executives. Our motto is: everybody builds, everybody plays."

The extended agreement is a strategic move solidifying the commitment of both Boundless and Freedom to work hand-in-hand to capture a significant increase in the solar energy market share.

"Our mission has always been to drive down costs and bring solar to the masses. Boundless has been an integral part of our growth, and this partnership provides a level of stability and longevity that further enables us to accomplish our overall mission," Brett Bouchy, CEO of Freedom Forever, added.

This integration immediately enables both organizations to further drive down costs and increase the already tangible competitive advantages.

With roughly 3000 employees at Freedom and approximately 500 at Boundless, the partnership is expected to immediately create additional job opportunities, contributing to economic growth and development.

Chad Towner, CRO of Freedom Forever, expressed enthusiasm for the partnership, stating, "We’re excited to deepen the partnership and focus on stability, which definitely results in more job opportunities."

Traveller concluded, "Boundless + Freedom creates an unfair advantage in the marketplace. We have lower costs for customers, better compensation for employees, and we’re giving everyone an opportunity to be an owner. We’re putting our money where our mouth is."

Contact Information
Name: Riley Traveller
Company: Boundless Energy, Inc.
Address: 11 Apex Dr. Suite 301B, Marlborough, MA 01752
Email: press@boundlessinc.com
Website: https://boundlessinc.com

SOURCE: Boundless Energy, Inc.

View the original press release on accesswire.com

Previous Article

Artizan Joyeria Introduces: Start with the Heart Within – Celebrating Self-Love With Exclusive Jewelry Drops for Valentine’s Day

Next Article

Feet in the Mud, Head in the Sky: A Morning Among the Mangroves

Related Posts

Xiamen promotes high-quality BRI development

XIAMEN, China, July 8, 2022 /PRNewswire/ — A report from China Daily: As a key port city of the 21st Century Maritime Silk Road and the Silk Road Economic Belt, the coastal city of Xiamen in East China’s Fujian province  has made contentious efforts to expand and improve maritime corridors and enhance economic and trade exchanges […]

‫اتصال رئيس وزراء سانت كيتس ونيفيس، تيموثي هاريس، بمجتمع الأعمال في الشرق الأوسط

لندن، 18 نوفمبر 2021 / PRNewswire/ – يتواصل رئيس وزراء سانت كيتس ونيفيس، تيموثي هاريس، مع مجتمع الأعمال في الشرق الأوسط بعد سفره إلى دبي لحضور فعاليات متنوعة ترنو إلى تعزيز فرص الاستثمار في الجزيرتين. وشمل ذلك ترأس وفد إلى معرض دبي إكسبو 2020 للاحتفال باليوم الوطني لسانت كيتس ونيفيس، بالإضافة إلى الافتتاح الرسمي لسفارتها في […]

FDA Approves Direct Biologics to Proceed with a Landmark Phase 3 Acute Respiratory Distress Syndrome (ARDS) Trial

AUSTIN, Texas, April 26, 2022 /PRNewswire/ — Direct Biologics, a regenerative biotechnology company with a groundbreaking extracellular vesicle (EV) platform technology, announced today that the FDA has approved the company to proceed with its Phase 3 clinical trial using its investigational EV drug, ExoFlo, to treat Acute Respiratory Distress Syndrome (ARDS) due to Covid-19. Direct Biologics […]